StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)

Close on Nov 13, 2026Market cap $19.34MP/E –Yield –

Aytu BioPharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Aytu BioPharma's profit margin for the twelve months ending Jun 30, 2026 was -24.8%. For fiscal 2026 it was -24.8%, against -20.4% the year before. The highest annual figure on record is -15.9% in fiscal 2023.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2026Jun 30, 2026-24.8%−4.3
FY2025Jun 30, 2025-20.4%+3.9
FY2024Jun 30, 2024-24.3%−8.4
FY2023Jun 30, 2023-15.9%+96.7
FY2022Jun 30, 2022-112.5%−23.7
FY2021Jun 30, 2021-88.8%−39.5
FY2020Jun 30, 2020-49.3%+321.3
FY2019Jun 30, 2019-370.6%−92.3
FY2018Jun 30, 2018-278.3%+420.3
FY2017Jun 30, 2017-698.7%+401.1
FY2016Jun 30, 2016-1099.7%+1850.6
FY2015Jun 30, 2015-2950.3%+325.0
FY2013Aug 31, 2013-3275.3%+134.7
FY2012Aug 31, 2012-3410.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jun 30, 2026-0.1%+130.8
Q3 FY2026CQ1 2026Mar 31, 2026-45.3%−66.9
Q2 FY2026CQ4 2025Dec 31, 2025-69.8%−74.7
Q1 FY2026CQ3 2025Sep 30, 202514.1%+5.3
Q4 FY2025CQ2 2025Jun 30, 2025-130.9%−99.3
Q3 FY2025CQ1 2025Mar 31, 202521.6%+42.2
Q2 FY2025CQ4 2024Dec 31, 20244.9%+6.0
Q1 FY2025CQ3 2024Sep 30, 20248.9%+54.5
Q4 FY2024CQ2 2024Jun 30, 2024-31.6%−23.6
Q3 FY2024CQ1 2024Mar 31, 2024-20.6%+11.1
Q2 FY2024CQ4 2023Dec 31, 2023-1.2%+24.3
Q1 FY2024CQ3 2023Sep 30, 2023-45.6%−43.0
Q4 FY2023CQ2 2023Jun 30, 2023-8.0%+50.6
Q3 FY2023CQ1 2023Mar 31, 2023-31.7%+188.5
Q2 FY2023CQ4 2022Dec 31, 2022-25.5%+24.5
Q1 FY2023CQ3 2022Sep 30, 2022-2.5%+124.7
Q4 FY2022CQ2 2022Jun 30, 2022-58.6%+22.3
Q3 FY2022CQ1 2022Mar 31, 2022-220.2%−31.4
Q2 FY2022CQ4 2021Dec 31, 2021-49.9%+12.9
Q1 FY2022CQ3 2021Sep 30, 2021-127.2%−95.3
Q4 FY2021CQ2 2021Jun 30, 2021-80.9%−59.7
Q3 FY2021CQ1 2021Mar 31, 2021-188.8%−123.5
Q2 FY2021CQ4 2020Dec 31, 2020-62.9%−56.1
Q1 FY2021CQ3 2020Sep 30, 2020-31.8%+310.5
Q4 FY2020CQ2 2020Jun 30, 2020-21.2%+825.8
Q3 FY2020CQ1 2020Mar 31, 2020-65.4%+123.7
Q2 FY2020CQ4 2019Dec 31, 2019-6.7%+252.7
Q1 FY2020CQ3 2019Sep 30, 2019-342.3%−101.6
Q4 FY2019CQ2 2019Jun 30, 2019-847.0%−906.1
Q3 FY2019CQ1 2019Mar 31, 2019-189.1%+274.8
Q2 FY2019CQ4 2018Dec 31, 2018-259.5%+89.9
Q1 FY2019CQ3 2018Sep 30, 2018-240.7%+153.7
Q4 FY2018CQ2 2018Jun 30, 201859.1%+866.7
Q3 FY2018CQ1 2018Mar 31, 2018-463.8%+119.9
Q2 FY2018CQ4 2017Dec 31, 2017-349.4%+257.2
Q1 FY2018CQ3 2017Sep 30, 2017-394.4%+425.8
Q4 FY2017CQ2 2017Jun 30, 2017-807.6%–
Q3 FY2017CQ1 2017Mar 31, 2017-583.8%–
Q2 FY2017CQ4 2016Dec 31, 2016-606.6%–
Q1 FY2017CQ3 2016Sep 30, 2016-820.1%–

More Aytu BioPharma figures

See a number that looks wrong?